News

November 6, 2019

First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer

News

A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company ... Read more

November 4, 2019

Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests

News

Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who have ... Read more

November 1, 2019December 30, 2019

Pathologist Creates Program Allowing Patients to Face Their Cancer Head-on

News

Massachusetts pathologist Lija Joseph, MD, has created an innovative program that allows patients, including those with breast cancer, to actually see the cells that make up their malignancies. In doing ... Read more

October 30, 2019

Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows

News

People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination ... Read more

October 28, 2019October 28, 2019

FDA Supports Use of Anti-diarrheal Medications with Nerlynx

News

The U.S. label of Nerlynx (neratinib), a treatment for early stage HER2-positive breast cancer, now includes information on the use of two anti-diarrheal medications to prevent severe side effects of the therapy. ... Read more

October 25, 2019November 11, 2019

Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows

News

Bempegaldesleukin (bempeg, NKTR-214) in combination with Opdivo (nivolumab) leads to prolonged treatment responses in women with advanced or metastatic triple-negative breast cancer (TNBC), a Phase 1/2 trial shows. The findings ... Read more

October 23, 2019October 24, 2019

Daiichi Sankyo Files New Drug Application for DS-8201 in Japan

News

Daiichi Sankyo has submitted an application to Japanese regulatory authorities asking that its investigational therapy trastuzumab deruxtecan (DS-8201) be approved as a treatment for people with HER2-positive metastatic breast cancer. ... Read more

October 21, 2019December 30, 2019

Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency has ... Read more

October 18, 2019October 28, 2019

Keytruda-chemo Combo Best for Clearing Tumors in Early TNBC, Latest Trial Data Show

News

Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or ... Read more

October 16, 2019

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. ... Read more